Hennion & Walsh Asset Management, Inc. Tg Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 98,629 shares of TGTX stock, worth $3.39 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
98,629
Previous 101,369
2.7%
Holding current value
$3.39 Million
Previous $1.8 Million
27.9%
% of portfolio
0.11%
Previous 0.1%
Shares
15 transactions
Others Institutions Holding TGTX
# of Institutions
339Shares Held
88.5MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$529 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$392 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$313 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$123 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$110 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...